Consegna Pharma Acquires Fathom Pharma

Delphia Acquires Fathom Privacy

October 1, 2022

Data & Analytics

Delphia, a membership-based investment collective, acquired data-rights company Fathom Privacy in a deal that closed in October 2022. Delphia will integrate Fathom's privacy and data-portability technology to give members greater control over their personal application data and strengthen Delphia's data-driven investment capabilities.

CORE Industrial Partners Completes Take-Private of Fathom Digital Manufacturing

May 22, 2024

Manufacturing

CORE Industrial Partners completed a take-private acquisition of Fathom Digital Manufacturing Corporation, resulting in Fathom Class A common stock ceasing to trade on the NYSE. CORE — a Chicago-based industrials-focused private equity firm and long-time partner of Fathom since 2018 — will continue to support the company's growth and development of its on-demand digital manufacturing capabilities across additive, CNC, injection molding and sheet metal services.

Scale LLP Merges with Fathom Law

June 18, 2025

Legal Services

Scale LLP has merged with San Francisco-based Fathom Law, adding six attorneys and strengthening Scale's corporate and emerging companies/venture capital (EC/VC) practice. The deal expands Scale's national bench to roughly 80 attorneys and deepens its capabilities to serve startups and venture-backed companies across financing and M&A matters.

Fathom (CORE Portfolio Company) Acquires Summit Tooling & Summit Plastics

February 3, 2021

Manufacturing

Fathom, a CORE Industrial Partners portfolio company, has acquired Summit Tooling, Inc. and Summit Plastics, Inc., a McHenry, Illinois-based provider of precision tooling and close-tolerance injection molding specializing in small-to-medium prototype molds. The deal is the fourth add-on to the Fathom platform and expands Fathom’s domestic quick-turn injection molding and tooling capabilities; Monroe Capital provided financing and Winston & Strawn LLP served as legal counsel.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Olympus Partners Acquires PAI Pharma

February 24, 2025

Pharmaceuticals

Olympus Partners has acquired PAI Pharma, a leading U.S. developer, manufacturer and distributor of generic oral liquid medicines. The platform was previously owned by Enhanced Healthcare Partners and Bourne Partners Strategic Capital; terms were not disclosed and Monroe Capital provided senior financing for the deal.